Brought to you by 
Public ADS offering nets $758mm for BeiGene
16 Feb 2018
Executive Summary
BeiGene (Beijing) Co. Ltd. (immuno-oncology) netted $758mm through the public sale of 7.9mm American Depositary Shares (representing 103mm common; including the overallotment) priced at $101 per ADS. Proceeds will support general corporate needs. Earlier this month, BeiGene announced a commercial supply agreement with Boehringer Ingelheim for manufacturing by BI of BeiGene's tislelizumab (solid and blood cancers), and it also disclosed details of an exclusive licensing deal for Mirati's tyrosine kinase inhibitor sitravatinib (solid tumors including NSCLC).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public ADS offering nets $758mm for BeiGene
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice